Sage Journals: Discover world-class research

Abstract

Objective:

To evaluate the role of ranolazine as an effective and safe first-line treatment option for the management of chronic stable angina (CSA).

Data Sources:

A literature search was conducted using MEDLINE (1966-August 2009), International Pharmaceutical Abstracts (1970-August 2009), and Cochrane database (publications archived until August 2009) using the terms chronic stable angina and ranolazine. In addition, reference citations from publications identified were reviewed.

Study Selection and Data Extraction:

English-language, randomized, controlled trials evaluating ranolazine extended release (ER) for the treatment of CSA in humans were selected for review. Four randomized controlled trials were identified. Findings pertaining to efficacy and safety were extracted.

Data Synthesis:

Three randomized, placebo-controlled CSA studies (N = 191, N = 823, N = 565) and 1 non-ST-segment elevation acute coronary syndrome (ACS) study (N = 6560) were identified that evaluated ranolazine ER. The 3 CSA studies showed that ranolazine ER treatment resulted in statistically significant improvements in exercise tolerance, time to angina onset, and time to 1-mm ST-segment depression. Two of the 3 CSA studies showed statistically significant reductions in angina episodes per week and nitroglycerin use per week compared to placebo. No significant reduction in cardiovascular events was seen in the non-ST-segment elevation ACS study following 1 year of treatment with ranolazine ER. Evidence has demonstrated that monotherapy with ranolazine ER is effective in increasing exercise tolerance in patients with CSA. Ranolazine ER therapy added to traditional antianginal therapy has shown efficacy in increasing exercise tolerance and minimally decreasing angina frequency in clinical trials.

Conclusions:

Ranolazine ER should be used judiciously in the management of CSA and should not be used as a first-line agent routinely unless traditional therapy is contraindicated.

Get full access to this article

View all access options for this article.

References

Lloyd-Jones

Adams

Carthenon

. Heart disease and stroke statistics—2009 update: A report of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: e21–181.

Nash

. Ranolazine for chronic stable angina. Lancet 2008; 372: 1335–41.

Gibbons

Abrams

Chatterjee

. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 2003; 41: 159–68.

Fraker

Jr Fihn

, writing on behalf of the 2002 Chronic Stable Angina Writing Committee. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007; 116: 2762–72.

FDA approves new treatment for chest pain. http://www.fda.gov/bbs/topics/news/2006/NEW01306.html (accessed 2009 Jan 10).

Chaitman

Skettino

Parker

., for the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) Trial investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43: 1375–82.

Chaitman

Pepine

Parker

., for The Combination Assessment of Ranolazine in Stable Angina (CARISA) investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomised controlled trial. JAMA 2004; 291: 309–16.

Fox

Garcia

Parma

. Guidelines on the management of stable angina: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.

Belardinelli

Antzelevitch

Fraser

. Inhibition of late (sustained/persistent) sodium current: A potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J Suppl 2004; 6 (suppl I): 13–7.

10.

Dobesh

Trujillo

. Ranolazine: A new option in the management of chronic stable angina. Pharmacotherapy 2007; 27: 1659–76.

11.

Marrs

Saseen

. Debating the clinical benefits of ranolazine and its role in therapy. Pharmacotherapy 2008; 28: 85e–7e.

12.

Maier

. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: Inhibition of late I_Na using ranolazine. J Cardiovasc Pharmacol 2009; 54: 279–86.

13.

Stone

Gratsiansky

Blokhin

Huang

I-Z

Meng

. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol 2006; 48: 566–75.

14.

Morrow

Scirica

Karwatowska-Prokopczuk

. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-segment acute coronary syndromes. The MERLIN-TIMI 36 trial. JAMA 2007; 297: 1775–83.

15.

FDA approves ranexa for first line anti anginal use and adds new claims for reduction of ventricular arrhythmias, bradycardia, new atrial fibrillation and HbA1c. http://www.cvt.com/PressRelease.aspx?releaseID = 1222934&section = media (accessed 2009 Jan 10).

16.

Product information. Ranexa (ranolazine extended release tablets). Palo Alto, CA: CV Therapeutics Inc., December 2008.

17.

Boden

O'Rourke

Teo

. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503–16.

18.

Eid

Boden

. The evolving role of medical therapy for chronic stable angina. Curr Cardiol Rep 2008; 10: 263–71.

19.

Patel

Arora

. Utility of ranolazine in chronic stable angina patients. Vasc Health and Risk Manag 2008; 4: 819–24.

20.

Koren

Crager

Sweeney

. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007; 49: 1027–34.

21.

Wilson

Scirica

Braunwald

. Efficacy of ranolazine in patients with chronic angina. J Am Coll Cardiol 2009; 53: 1510–6.

22.

Bunch

Muhlestein

Bair

. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure. Am J Cardiol 2005; 95: 827–31.

23.

American College of Cardiology Practice Guideline Statements in Progress. http://www.acc.org/qualityandscience/clinical/progress/progress.html (accessed 2009 Aug 30).

Ranolazine's Role in the Treatment of Chronic Stable Angina